Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 57.36 CNY -3.3% Market Closed
Market Cap: 42.6B CNY
Have any thoughts about
Hangzhou Tigermed Consulting Co Ltd?
Write Note

Hangzhou Tigermed Consulting Co Ltd
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hangzhou Tigermed Consulting Co Ltd
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cash Taxes Paid
-ÂĄ611.4m
CAGR 3-Years
-26%
CAGR 5-Years
-25%
CAGR 10-Years
-30%
WuXi AppTec Co Ltd
SSE:603259
Cash Taxes Paid
-ÂĄ1.3B
CAGR 3-Years
-155%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cash Taxes Paid
-ÂĄ61.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
MGI Tech Co Ltd
SSE:688114
Cash Taxes Paid
-ÂĄ42.6m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Cash Taxes Paid
ÂĄ48.1m
CAGR 3-Years
75%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hangzhou Tigermed Consulting Co Ltd
Glance View

Market Cap
42.6B CNY
Industry
Life Sciences Tools & Services

Founded in 2004, Hangzhou Tigermed Consulting Co., Ltd. emerged as a pivotal player in the flourishing landscape of clinical research services within the pharmaceutical and biotechnology sectors. As a leading contract research organization (CRO), Tigermed has meticulously woven a fabric of comprehensive solutions that span from drug development to clinical trial management. Their expertise extends across various therapeutic areas, underpinning a business model that thrives on facilitating the intricate process through which innovative drugs make their way from concept to market. The company’s robust portfolio of services encompasses clinical operations, regulatory submissions, data management, and biostatistics, effectively addressing the myriad needs of drug development companies looking to streamline operations and accelerate time-to-market. Tigermed’s revenue model primarily revolves around contracts and partnerships with pharmaceutical and biotech companies seeking external expertise in clinical trials. The company's proficiency in managing multinational projects, especially within China and the broader Asia-Pacific region, provides an edge in a competitive global market that increasingly values speed and localized knowledge. Rather than merely providing traditional consulting services, Tigermed capitalizes on cutting-edge technology and a deep understanding of regional regulatory frameworks to offer a seamless and efficient trial process. In doing so, it captures the growing demand for outsourcing drug development work, ensuring steady revenue streams while solidifying its status as a vital partner in the relentless pursuit of medical innovation.

Intrinsic Value
69.85 CNY
Undervaluation 18%
Intrinsic Value
Price

See Also

What is Hangzhou Tigermed Consulting Co Ltd's Cash Taxes Paid?
Cash Taxes Paid
-611.4m CNY

Based on the financial report for Sep 30, 2024, Hangzhou Tigermed Consulting Co Ltd's Cash Taxes Paid amounts to -611.4m CNY.

What is Hangzhou Tigermed Consulting Co Ltd's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 10Y
-30%

Over the last year, the Cash Taxes Paid growth was 2%. The average annual Cash Taxes Paid growth rates for Hangzhou Tigermed Consulting Co Ltd have been -26% over the past three years , -25% over the past five years , and -30% over the past ten years .

Back to Top